These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
404 related items for PubMed ID: 25441336
1. Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach. Grupe M, Grunnet M, Bastlund JF, Jensen AA. Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):187-200. PubMed ID: 25441336 [Abstract] [Full Text] [Related]
2. α4β2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2 nAChR agonists in pain. Lee CH, Zhu C, Malysz J, Campbell T, Shaughnessy T, Honore P, Polakowski J, Gopalakrishnan M. Biochem Pharmacol; 2011 Oct 15; 82(8):959-66. PubMed ID: 21763685 [Abstract] [Full Text] [Related]
3. α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain. Nirogi R, Goura V, Abraham R, Jayarajan P. Eur J Pharmacol; 2013 Jul 15; 712(1-3):22-9. PubMed ID: 23660369 [Abstract] [Full Text] [Related]
5. Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor. Faghih R, Gfesser GA, Gopalakrishnan M. Recent Pat CNS Drug Discov; 2007 Jun 06; 2(2):99-106. PubMed ID: 18221220 [Abstract] [Full Text] [Related]
6. The subtype-selective nicotinic acetylcholine receptor positive allosteric potentiator 2087101 differentially facilitates neurotransmission in the brain. de Filippi G, Mogg AJ, Phillips KG, Zwart R, Sher E, Chen Y. Eur J Pharmacol; 2010 Sep 25; 643(2-3):218-24. PubMed ID: 20624387 [Abstract] [Full Text] [Related]
7. Allosteric modulation of α4β2* nicotinic acetylcholine receptors: Desformylflustrabromine potentiates antiallodynic response of nicotine in a mouse model of neuropathic pain. Bagdas D, Ergun D, Jackson A, Toma W, Schulte MK, Damaj MI. Eur J Pain; 2018 Jan 25; 22(1):84-93. PubMed ID: 28809075 [Abstract] [Full Text] [Related]
8. Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats. Zhu CZ, Chin CL, Rustay NR, Zhong C, Mikusa J, Chandran P, Salyers A, Gomez E, Simler G, Lewis LG, Gauvin D, Baker S, Pai M, Tovcimak A, Brown J, Komater V, Fox GB, Decker MW, Jacobson PB, Gopalakrishnan M, Lee CH, Honore P. Biochem Pharmacol; 2011 Oct 15; 82(8):967-76. PubMed ID: 21620806 [Abstract] [Full Text] [Related]
9. Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators. Wilkerson JL, Deba F, Crowley ML, Hamouda AK, McMahon LR. Neuropharmacology; 2020 May 15; 168():108008. PubMed ID: 32113032 [Abstract] [Full Text] [Related]
10. Allosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors. Pandya A, Yakel JL. Biochem Pharmacol; 2011 Oct 15; 82(8):952-8. PubMed ID: 21596025 [Abstract] [Full Text] [Related]
11. Discovery of an intrasubunit nicotinic acetylcholine receptor-binding site for the positive allosteric modulator Br-PBTC. Norleans J, Wang J, Kuryatov A, Leffler A, Doebelin C, Kamenecka TM, Lindstrom J. J Biol Chem; 2019 Aug 09; 294(32):12132-12145. PubMed ID: 31221718 [Abstract] [Full Text] [Related]
12. Allosteric modulation of nicotinic acetylcholine receptors. Chatzidaki A, Millar NS. Biochem Pharmacol; 2015 Oct 15; 97(4):408-417. PubMed ID: 26231943 [Abstract] [Full Text] [Related]
13. Central nicotinic receptors: structure, function, ligands, and therapeutic potential. Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F. ChemMedChem; 2007 Jun 15; 2(6):746-67. PubMed ID: 17295372 [Abstract] [Full Text] [Related]
14. Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them. Xiao Y, Fan H, Musachio JL, Wei ZL, Chellappan SK, Kozikowski AP, Kellar KJ. Mol Pharmacol; 2006 Oct 15; 70(4):1454-60. PubMed ID: 16857741 [Abstract] [Full Text] [Related]
15. Selective potentiation of (α4)3(β2)2 nicotinic acetylcholine receptors augments amplitudes of prefrontal acetylcholine- and nicotine-evoked glutamatergic transients in rats. Grupe M, Paolone G, Jensen AA, Sandager-Nielsen K, Sarter M, Grunnet M. Biochem Pharmacol; 2013 Nov 15; 86(10):1487-96. PubMed ID: 24051136 [Abstract] [Full Text] [Related]
16. Allosteric modulation of alpha4beta2 nicotinic acetylcholine receptors by HEPES. Weltzin MM, Huang Y, Schulte MK. Eur J Pharmacol; 2014 Jun 05; 732():159-68. PubMed ID: 22732654 [Abstract] [Full Text] [Related]
17. The α7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets? Thomsen MS, Mikkelsen JD. Curr Drug Targets; 2012 May 05; 13(5):707-20. PubMed ID: 22300038 [Abstract] [Full Text] [Related]
18. Behavioral and Molecular Basis of Cholinergic Modulation of Pain: Focus on Nicotinic Acetylcholine Receptors. Toma W, Ulker E, Alqasem M, AlSharari SD, McIntosh JM, Damaj MI. Curr Top Behav Neurosci; 2020 May 05; 45():153-166. PubMed ID: 32468494 [Abstract] [Full Text] [Related]
19. Pharmacological characterization of the allosteric modulator desformylflustrabromine and its interaction with alpha4beta2 neuronal nicotinic acetylcholine receptor orthosteric ligands. Weltzin MM, Schulte MK. J Pharmacol Exp Ther; 2010 Sep 01; 334(3):917-26. PubMed ID: 20516140 [Abstract] [Full Text] [Related]
20. Allosteric modulation of nicotinic acetylcholine receptors. Bertrand D, Gopalakrishnan M. Biochem Pharmacol; 2007 Oct 15; 74(8):1155-63. PubMed ID: 17707779 [Abstract] [Full Text] [Related] Page: [Next] [New Search]